Arcus BiosciencesRCUS
RCUS
About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Employees: 674
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
2,888% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $885K
69% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 49
6% more capital invested
Capital invested by funds: $763M [Q1] → $808M (+$45.3M) [Q2]
2.0% more ownership
Funds ownership: 91.8% [Q1] → 93.8% (+2.0%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
2% less funds holding
Funds holding: 185 [Q1] → 181 (-4) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$25
146%
upside
Avg. target
$25
146%
upside
High target
$25
146%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Eva Fortea Verdejo | 146%upside $25 | Overweight Maintained | 7 Aug 2025 |
Financial journalist opinion
Based on 6 articles about RCUS published over the past 30 days
Neutral
Business Wire
5 days ago
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September: Citi's 2025 Biotech Back to School Conference Date: Wednesday, September 3rd, 2025 Location: Boston, MA Format: Fireside chat & 1x1 meetings Time: 11:15 a.m. ET H.C. W.
Positive
Benzinga
1 week ago
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Uranium Energy Corp. UEC, saying, “I like nuclear.”
Positive
Seeking Alpha
2 weeks ago
Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months
Arcus Biosciences is at a critical juncture, with multiple late-stage assets and a cash position nearly equal to its market cap. Casdatifan shows best-in-class potential in renal cell carcinoma, with pivotal Phase 3 data expected within 12 months to determine commercial viability. Ongoing Phase 3 studies for domvanalimab and quemliclustat offer significant catalysts, with key data readouts anticipated in 2026.
Positive
The Motley Fool
2 weeks ago
Arcus (RCUS) Q2 Revenue Jumps 310%
Arcus (RCUS) Q2 Revenue Jumps 310%
Neutral
Zacks Investment Research
2 weeks ago
Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2
Arcus Biosciences, Inc. (RCUS) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $1.02 per share a year ago.
Neutral
Business Wire
2 weeks ago
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers. “We have now presented data from over 125 patients treated with casdatifan monotherapy or.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Company's common stock at an exercise price per share of $9.75, which was the closing price on July 23, 2025, and rest.
Neutral
Business Wire
1 month ago
Arcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer. “The orphan drug designation indicates the importance of developing new tre.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 54,800 shares of the Company's common stock at an exercise price per share of $8.50, which was the closing price on July 8, 2025, and restr.
Neutral
Business Wire
2 months ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common stock at an exercise price per share of $8.63, which was the closing price on June 23, 2025, and restri.
Charts implemented using Lightweight Charts™